Abiopharma

News list

FOGHORN THERAPEUTICS INC. (FHTX)

SEC News
March 11, 2026, 20:09 UTC

(90% Positive) FOGHORN THERAPEUTICS INC. (FHTX) Announces Enrollment Update for financing Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text

News bot March 11, 2026, 8:13 p.m.

📋 FOGHORN THERAPEUTICS INC. (FHTX) - Clinical Trial Update

Filing Date: 2026-03-11

Accepted: 2026-03-11 16:09:11

Event Type: Clinical Trial Update

Event Details:

FOGHORN THERAPEUTICS INC. (FHTX) Announces Clinical Trial Update FOGHORN THERAPEUTICS INC. (FHTX) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: financing, focus
Diseases/Conditions: oncology
Clinical Stage: Phase 1
Collaboration: DocumentExhibit 99.1Foghorn Therapeutics Provides Financial Update
Updated Timeline: the year ending December 31, 2025, December 31, 2025
- targeting cancers with significant unmet needs,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Our lead candidate FHD-909 continues to progress as planned through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA4 mutations, where outcomes remain especially poor and deteriorate with later lines of therapy. In parallel, our wholly owned programs are moving toward the clinic. Our Selective CBP degrader program and our Selective EP300 degrader are on track for IND-enabling studies in 2026
- anticipated in 2026
- targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.Forward-Looking StatementsThis press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers, pre-clinical product candidates, expected timing of clinical data, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025

🔬 Clinical Development Pipeline (FOGHORN THERAPEUTICS INC.):

Product	Type	Development Stage	Therapeutic Area	Source
FHD-286	DRUG	Phase PHASE1	Acute Myeloid Leukemia	ClinicalTrials.gov
Venetoclax	DRUG	Phase PHASE1	Acute Myeloid Leukemia	ClinicalTrials.gov
Decitabine	DRUG	Phase PHASE1	Acute Myeloid Leukemia	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval: Not available
Executive Changes: Not available

Structured Data:

Company Name: FOGHORN THERAPEUTICS INC.
Ticker Symbol: FHTX